IRS1 and neoplasm: Finally, as an insulin feedback was reported to limit the efficacy of PI3K inhibition in several tumor models (Hopkins et al., 2018), we checked for the effects of the combined PIK‐75 plus vemurafenib therapy on the expression of the IRS‐1.